New plan to tackle antimicrobial resistance launched

A new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat, has been launched today.

The National Action Plan will commit the UK to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals, strengthen surveillance of drug-resistant infections before they emerge and incentivize industry to develop the next generation of treatments.

It commits to continue to innovate through initiatives such as indicating that the world-first 'subscription model' for antimicrobials, which was launched in 2019 as a pilot, could be expanded. This will see more companies paid a fixed annual fee for antimicrobials based primarily on their value to the NHS, as opposed to the volumes used.

The plan will build on progress towards the UK's 20-year vision for antimicrobial resistance which will see AMR contained, controlled and mitigated - protecting public health by increasing the risk of disease spread, severe illness, disability and death.  

Almost 8,000 people in the UK die from drug resistant infections every year.  If this continues to spread, common infections and injuries that were once easily treatable become harder, and in some cases impossible, to treat.    

Our five-year action plan outlines our commitment to leading the way in tackling AMR, including through expanding our world-first subscription model to accelerate research into new treatments.

In a world recovering from the profound impact of the COVID-19 pandemic, international collaboration and preparedness for global health challenges have taken on an unprecedented level of importance."

Maria Caulfield, Health Minister

This is the second of a series of five-year National Action Plans that will ensure sustained progress by tackling the global threat of AMR.

Learning from the achievements and challenges faced in delivering the previous plan, which was launched in 2019, this new National Action Plan will run from 2024 to 2029. It embeds lessons from the COVID-19 pandemic and will include specific commitments focusing on infection prevention and control, and the development and use of diagnostics and vaccines.

Action has already been taken across sectors, including the medical and farming industries, to decrease the number of infections and prevent antimicrobial resistance from spreading.

The new plan has nine strategic outcomes organized under four themes:

Reducing the need for, and unintentional exposure to, antimicrobials - this includes activity to prevent infections arising in the first place (through good infection prevention and control, including vaccination), to monitor the emergence and spread of AMR through strengthened surveillance, and to minimize release of antimicrobials and resistance into the environment.

  • Optimizing the use of antimicrobials - through ensuring antimicrobials are only used when needed in humans, animals, and the environment.
  • Investing in innovation, supply and access - by supporting and incentivizing the development of new vaccines, diagnostics and therapeutics (including alternatives to antimicrobials), making them accessible to those who need them, and ensuring our work on AMR is informed by cutting-edge research.
  • Being a good global partner - maintaining the UK's role as an international leader on AMR and supporting low- and middle-income countries to respond to the threat of AMR through research, good supply chains and access to antibiotics.

AMR occurs when bacteria, and other microorganisms, develop resistance to antimicrobial drugs, such as antibiotics, making them less responsive or unresponsive to treatment. Avoiding unnecessary antibiotic usage in humans and animals is crucial to slowing the development and spread of antibiotic resistance.

In 2022, the government invested £210 million to partner with countries across Asia and Africa to tackle AMR and reduce the threat posed to the UK, through the Fleming Fund.

It is estimated that in 2019, 1.27 million deaths globally were caused by infections resistant to antibiotics. The UK is committed to playing a central role in the global effort to confront AMR by taking a comprehensive approach that leverages the country's expertise and domestic experience.

The scale of the AMR threat, and the need to contain and control it, is widely acknowledged by governments, international agencies, including the WHO and World Bank, researchers and private companies alike. 

Chief Medical Officer Professor Chris Whitty said:

Antibiotics are one of the most powerful tools we have against infection. Resistance to these drugs therefore poses a significant threat to the lives of many people in the UK and around the world.

AMR is not just a matter for clinicians - it is important to work across sectors to help preserve these vital medicines to minimize the impact of AMR."

UK Special Envoy on AMR Dame Sally Davies said:

It is incomprehensible for any of us to imagine a world without effective antibiotics.

But we are facing an antibiotic emergency already. And this menace is deeply unfair - with the burden disproportionately falling on the world's most vulnerable, in low-and middle-income countries and also children.

We have to work together, across the world, with those countries that need action the most, to make progress and contain AMR."

Professor Susan Hopkins, Chief Medical Advisor at the UK Health Security Agency, said:

Antimicrobial resistance is a threat to all of us - simple lifesaving interventions in the form of antimicrobials are in danger of becoming ineffective.

Through our priority AMR programme, including one health surveillance, collaborative working with the health service, international collaborations and novel approaches to therapies and diagnostics, UKHSA has risen to meet this active threat - but it will take collective action across government, industry, academia and the public to ensure that antimicrobials remain available for ourselves and our communities, now and in the future."

The Deputy Prime Minister, Oliver Dowden said:

Antimicrobial resistance is the invisible threat we must tackle to protect the welfare of our society and safeguard the NHS.

I am pleased to see the publication of this second National Action Plan, which fulfils our commitments in the Biological Security Strategy to progress towards the vision of a world where AMR is effectively contained, controlled and mitigated by 2040."

UK Chief Veterinary Officer Christine Middlemiss said:

The UK has made fantastic progress in the past 10 years to reduce AMR in animals, working between government, farming industry, vets, and animal keepers to reduce the use of antibiotics in food-producing animals by more than half.

The new National Action Plan will build upon these achievements, and I urge vets and animal keepers to continue to support the UK's 20-year vision to contain and control AMR."

Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry said: 

Antimicrobial resistance is a pressing health challenge which requires urgent global action. The UK has been proactive in finding practical solutions to this problem, and this new National Action Plan sets a precedent that countries worldwide should follow.

Expanding the pilot of the innovative antibiotic subscription model is a crucial next step with our industry's full support. This type of innovative thinking is needed to address the issues associated with AMR and safeguard public health from this shared threat".

James Anderson, Executive Director, Global Health at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Chair of the AMR Industry Alliance said:

Tackling the rising threat of antimicrobial resistance will depend on having a continuous pipeline that delivers new, innovative antibiotics.

To do this, society needs to take bold action to redefine the value we place on them and attract more R&D investment.

The successful results of the UK's pilot programme provide an important reference point ahead of this year's UN High-Level Meeting on AMR. As a truly global challenge, we need to see countries working together to make a step change in how the world is addressing AMR."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research finds microplastics in human penile tissue